Announced
Completed
Financials
Tags
microbiome
Acquisition
Natural
Israel
Pharmaceuticals
Private
pharmaceuticals
Single Bidder
Majority
Completed
De-SPAC
Synopsis
Chardan Healthcare Acquisition, a special purpose acquisition company, completed the $134m acquisition of BiomX, a microbiome company developing both natural and engineered phage therapies. $134m reflects value of Equity and Net Cash of BiomX "We believe this transaction leaves BiomX with a strong balance sheet and sufficient cash for the company to reach multiple value inflection points in its leading clinical programs. We also believe we have structured a transaction that will deliver value to all stakeholders and create opportunity for new investors. We are excited to make use of inherent features of the SPAC in combination with the fundamental qualities of BiomX and supportive shareholders for the benefit of all of our partners." Jonas Grossman, CHAC's President and Chief Executive Officer.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.